계명대학교 의학도서관 Repository

Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era

Metadata Downloads
Author(s)
Ga-Young Song Sang Eun Yoon Seok Jin Kim Jin Seok Kim Youngil Koh Joon-Ho Moon Sung Yong Oh Ho Sup Lee Ho-Jin Shin Young Rok Do Won Sik Lee Dae Sik Kim Yong Park Ho-Young Yhim Deok-Hwan Yang
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Scientific Reports
Issued Date
2020
Volume
10
Issue
1
Abstract
There are still controversies about the use of interim positron emission tomography/computed tomography (PET/CT) in indolent non-Hodgkin lymphoma due to the variable fluorodeoxyglucose (FDG) avidity. Therefore, this study aimed to evaluate the roles of interim PET/CT in marginal zone lymphoma (MZL), a representative indolent lymphoma. We analyzed the data of 146 MZL patients. All were treated with rituximab-containing immunochemotherapy. Interim PET/CT scan was performed after 2-3 cycles of therapy, and the response was assessed using the Deauville 5-point scales (5-PS) and a semi-quantitative assessment using the SUVmax reduction rate (ΔSUVmax). Progression-free survival (PFS) was well stratified according to a visual assessment of interim PET/CT using 5-PS (p < 0.001). Particularly, there was a significant difference in PFS between patients with interim score 1-2 and those with score 3. However, ΔSUVmax did not predict the survival outcome using 59.8% of the optimal cutoff value. In the multivariate analysis, failure to achievement of grade 1-2 in interim PET/CT was significantly associated with inferior PFS (HR, 2.154; 95% CI 1.071-4.332; p = 0.031). The interim PET/CT response based on the 5-PS is useful for predicting PFS of patients with MZL in the post-rituximab era.
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine (의과대학)
Citation
Ga-Young Song et al. (2020). Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. Scientific Reports, 10(1), 11649. doi: 10.1038/s41598-020-68310-w
Type
Article
ISSN
2045-2322
Source
https://www.nature.com/articles/s41598-020-68310-w
DOI
10.1038/s41598-020-68310-w
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43300
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.